Nedocromil in the Outpatient Management of Asthma

Document Type

Article

Publication Title

Archives of Family Medicine

Abstract

Objective: To more closely approximate the use of a nonsteroidal inhaled anti-inflammatory medication for asthma, nedocromil sodium, under actual ambulatory practice conditions.

Design: Large, open-label trial.

Patients: One thousand two hundred one patients from 286 primary care and specialty centers.

Intervention: Four weeks of treatment with nedocromil sodium (4 mg delivered from the valve and 3.5 mg delivered from the mouthpiece of a metered inhalor [2 puffs, four times daily]).

Main outcome measures: Asthma symptom scores, peak expiratory flow rate, a lifestyle assessment measures questionnaire, and mean number of days missed per month from work or school.

Results: Statistically significant improvements were seen after 1 and 4 weeks of treatment for cough, daytime and nighttime asthma, morning tightness, peak expiratory flow rate, and all four measured lifestyle assessment factors (P < .001). An additional clinically relevant outcome measure, mean number of days missed per month from work or school, was reduced by 75% (P < .001). No serious adverse reactions were reported.

Conclusion: This study reproduces the high level of efficacy and safety of nedocromil that was previously reported in placebo-controlled clinical studies.

DOI

10.1001/archfami.4.10.835

Publication Date

10-1995

ISSN

1063-3987

Share

COinS